FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 03:00:07 2024-05-17 am EDT | ||
| 1.3 EUR / 1.4 EUR | +2.27% |
|
| Current month | -63.54% | ||
| 1 month | -64.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-16 | 1.32 | -7.04% |
| 24-05-15 | 1.42 | -15.48% |
| 24-05-14 | 1.68 | 0.00% |
| 24-05-13 | 1.68 | -13.85% |
| 24-05-10 | 1.95 | -4.88% |
Delayed Quote Börse Stuttgart
Last update May 16, 2024 at 03:43 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK205E |
| ISIN | DE000JK205E5 |
| Date issued | 2024-02-23 |
| Strike | 495.7 $ |
| Maturity | Unlimited |
| Parity | 41.21 : 1 |
| Emission price | 2.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.07 € |
|---|---|
| Lowest since issue | 1.32 € |
| Spread | 0.1 € |
| Spread % | 7.09% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Certificates
- Certificat
